Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Somapacitan (Sogroya) vs Tesamorelin
An educational, source-based comparison of Somapacitan (Sogroya) and Tesamorelin — how each peptide works, what it's researched for, and what to know before going deeper.
Once-weekly growth hormone analog for adults and children with GHD.
GH analog with a non-covalent albumin-binding side chain that extends half-life, enabling once-weekly subcutaneous administration with sustained IGF-1 elevation.
- Adult growth hormone deficiency
- Pediatric GH deficiency
- • FDA-approved.
- • Monitor glucose; injection-site reactions possible.
A stabilized analog of growth hormone-releasing hormone (GHRH) that stimulates pulsatile endogenous GH and IGF-1 release. FDA-approved (Egrifta) for the reduction of excess abdominal visceral fat in HIV-infected patients with lipodystrophy.
- Visceral adipose tissue reduction (approved)
- Cognitive function in older adults (research)
- NAFLD / hepatic fat (research)
- • FDA-approved only for HIV-associated lipodystrophy.
- • May affect glucose tolerance; monitor in at-risk patients.
- • Requires physician oversight.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Somapacitan (Sogroya) | REAL trials | JCEM | 2020 | Comparable body composition and IGF-1 response to daily somatropin. |
| Tesamorelin | Tesamorelin for HIV-associated lipodystrophy | New England Journal of Medicine | 2007 | Phase 3 trials showing significant visceral fat reduction. |
| Tesamorelin | Tesamorelin and NAFLD in HIV | The Lancet HIV | 2019 | Reduced hepatic fat fraction in HIV-infected adults with NAFLD. |
Side-effect & safety grid
- FDA-approved.
- Monitor glucose; injection-site reactions possible.
- FDA-approved only for HIV-associated lipodystrophy.
- May affect glucose tolerance; monitor in at-risk patients.
- Requires physician oversight.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Somapacitan (Sogroya) vs Tesamorelin — Key differences
- Class: Somapacitan (Sogroya) is classified as GH Analog · Endocrine, while Tesamorelin is Growth Hormone Axis.
- Primary research focus: Somapacitan (Sogroya) — adult growth hormone deficiency; Tesamorelin — visceral adipose tissue reduction (approved).
- Tag: FDA-Approved · Endocrine vs Body composition.